Coulgen Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 14 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -42.07%
- Profit Growth -980.63%
- Ebitda -545.25%
- Net Worth -136.97%
- Total Assets -48.99%
About Coulgen Biotech
Coulgen Biotech Private Limited (CBPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 July 2010 and has a history of 14 years and seven months. Its registered office is in Delhi, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Debjani Kundu and Debjit Kundu serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74900DL2010PTC206129
- Company No.
206129
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Jul 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Coulgen Biotech Private Limited offer?
Coulgen Biotech Private Limited offers a wide range of products and services, including Analyzers & Analytical Instruments, PH Meter, Elemental Analyzer, Electrical & Electronic Test Devices, Conductivity Meter, Measuring Equipments & Instruments, Measurement Instrument, Thermometers & Flowmeters, Viscosity Instruments, Medical Laboratory Instruments.
Who are the key members and board of directors at Coulgen Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Debjani Kundu  | Director | 21-Jul-2010 | Current |
| Debjit Kundu | Director | 21-Jul-2010 | Current |
Financial Performance of Coulgen Biotech.
Coulgen Biotech Private Limited, for the financial year ended 2019, experienced significant reduction in revenue, with a 42.07% decrease. The company also saw a substantial fall in profitability, with a 980.63% decrease in profit. The company's net worth observed a substantial decline by a decrease of 136.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Coulgen Biotech?
In 2019, Coulgen Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Coulgen Biotech?
Unlock and access historical data on people associated with Coulgen Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Coulgen Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Coulgen Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.